PHE News

Precision’s Snider Interviewed by AJMC Regarding New CAR-T Societal Value Study

A new Precision Health Economics-authored study on the societal value of CAR-T therapy is generating a significant level of interest within the scientific community.

READ MORE

New PHE Study Released on Cost of Nonadherence

A novel approach to measuring the cost of nonadherence is outlined in a new article by Precision experts Jason Shafrin, Ross Maclean, and colleagues.

READ MORE

Precision's Shafrin Writes of the Value of Real-World Evidence in Drug Discovery & Development

In a new article for Drug Discovery & Development, Precision Health Economics senior research economist Jason Shafrin addresses the use of real-world evidence, why we need it and how to effectively implement it.

READ MORE

POLITICO Pulses on Launch of IVI's New Open-Source Value Tool

Must-read morning briefing POLITICO Pulse talks with Innovation & Value Initiative (IVI) executive director Darius Lakdawalla on the launch of a first-of-its-kind open-source project for determining the value of medical treatments.

READ MORE

View Our Free, On-Demand Webinar!

PHE Chief Scientific Officer Darius Lakdawalla and Research Economist Tiffany Shih take us beyond traditional cost-effectiveness analysis in this free, hour-long recorded webinar.

READ MORE
 
  • Academic Insights at

    the Speed of Business

     
  • Intellectual Integrity

    Led by professors at elite research universities, we bring intellectual integrity, academic rigor, and a creative approach to the most challenging problems in heath care.

     
  • Real World Impact

    PHE recommendations have defined and changed national and international payment policies.

     
  • Unparalleled Influence

    We frequently appear in top-tier publications and media outlets-- our work reaches top decision makers and influences outcomes.

     
  • Evidence Generation and

    Commercial Excellence

    As part of Precision for Value, our academic approach to research can be linked with a tailored, commercial approach that demonstrates the value of innovative medications.

     
  • Academic Insights at

    the Speed of Business